PIACENTINI, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.887
EU - Europa 13.176
AS - Asia 8.866
SA - Sud America 1.293
AF - Africa 211
OC - Oceania 67
Continente sconosciuto - Info sul continente non disponibili 23
Totale 43.523
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.614
IT - Italia 4.102
CN - Cina 2.728
SG - Singapore 2.672
GB - Regno Unito 2.421
IE - Irlanda 2.190
HK - Hong Kong 1.298
DE - Germania 1.099
BR - Brasile 1.030
SE - Svezia 1.016
VN - Vietnam 583
RU - Federazione Russa 467
UA - Ucraina 377
FR - Francia 333
FI - Finlandia 299
ID - Indonesia 256
TR - Turchia 256
IN - India 241
BG - Bulgaria 169
KR - Corea 163
CA - Canada 157
NL - Olanda 156
JP - Giappone 110
TW - Taiwan 104
AR - Argentina 100
MX - Messico 76
PL - Polonia 75
IQ - Iraq 74
LT - Lituania 73
ES - Italia 68
AU - Australia 64
BE - Belgio 60
ZA - Sudafrica 58
BD - Bangladesh 54
EG - Egitto 48
MY - Malesia 46
IR - Iran 42
PK - Pakistan 41
AT - Austria 40
CZ - Repubblica Ceca 39
EC - Ecuador 37
CL - Cile 30
CO - Colombia 29
VE - Venezuela 29
CH - Svizzera 24
RO - Romania 24
PH - Filippine 21
SA - Arabia Saudita 20
IL - Israele 19
EU - Europa 17
PY - Paraguay 17
AE - Emirati Arabi Uniti 16
GR - Grecia 16
MA - Marocco 16
MD - Moldavia 16
HU - Ungheria 15
UZ - Uzbekistan 15
AL - Albania 14
JO - Giordania 14
KE - Kenya 14
NG - Nigeria 11
TH - Thailandia 11
TN - Tunisia 11
DK - Danimarca 10
DO - Repubblica Dominicana 10
DZ - Algeria 10
MK - Macedonia 10
AZ - Azerbaigian 9
ET - Etiopia 9
LV - Lettonia 9
PE - Perù 9
SI - Slovenia 9
PT - Portogallo 8
BO - Bolivia 7
NP - Nepal 7
PA - Panama 7
KZ - Kazakistan 6
LB - Libano 6
MT - Malta 6
RS - Serbia 6
SY - Repubblica araba siriana 6
CR - Costa Rica 5
GH - Ghana 5
HN - Honduras 5
KG - Kirghizistan 5
LA - Repubblica Popolare Democratica del Laos 5
NO - Norvegia 5
AM - Armenia 4
AO - Angola 4
GE - Georgia 4
IS - Islanda 4
KH - Cambogia 4
SK - Slovacchia (Repubblica Slovacca) 4
TZ - Tanzania 4
AP - ???statistics.table.value.countryCode.AP??? 3
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
BW - Botswana 3
HR - Croazia 3
KW - Kuwait 3
Totale 43.455
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.316
Dublin 2.184
Ashburn 1.883
Singapore 1.829
Fairfield 1.752
Chandler 1.433
Southend 1.325
Hong Kong 1.262
Woodbridge 1.011
Houston 780
Dearborn 735
Seattle 717
Nyköping 668
Ann Arbor 666
Hefei 644
Wilmington 619
Jacksonville 604
Beijing 572
Cambridge 535
London 511
Dallas 480
New York 380
Milan 361
Los Angeles 317
Modena 309
Rome 257
Jakarta 224
Munich 209
Chicago 193
Shanghai 186
Ho Chi Minh City 184
San Diego 180
Helsinki 179
Princeton 174
Bologna 168
Sofia 168
The Dalles 164
Moscow 151
Eugene 141
Seoul 136
Council Bluffs 131
Izmir 130
Hanoi 117
Dong Ket 112
Fremont 104
Redwood City 104
São Paulo 99
Buffalo 89
Frankfurt am Main 79
Bremen 77
Columbus 77
Naples 73
Falls Church 67
Guangzhou 66
Salt Lake City 65
Tokyo 60
Reggio Emilia 59
Boardman 58
Phoenix 57
Redondo Beach 57
Turin 56
Warsaw 56
Brooklyn 51
Florence 51
Brussels 49
Bari 48
Genoa 46
Parma 46
Tampa 45
Turku 44
Norwalk 43
Elk Grove Village 40
Nuremberg 40
Ottawa 37
Palermo 36
San Giuliano Milanese 35
Lauterbourg 34
Paris 34
Atlanta 33
Kent 33
Nanjing 33
Rio de Janeiro 33
Des Moines 32
Enfield 32
Orem 32
Baghdad 31
Montreal 31
Stockholm 31
Toronto 31
Padova 30
Portsmouth 30
San Francisco 30
Kunming 29
Porto Alegre 29
Johannesburg 28
Amsterdam 27
Taichung 27
Boston 26
Mumbai 26
Belo Horizonte 25
Totale 29.738
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.010
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 515
Abemaciclib: eventi avversi e riduzione di dose. 461
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 432
Oxford Manuale di Medicina Clinica 426
RISULTATI DELLA RADIOTERAPIA PANENCEFALICA (WBRT) NELLE METASTASI CEREBRALI DA CARCINOMA DELLA MAMMELLA: STUDIO RETROSPETTIVO SUL RUOLO PROGNOSTICO DEI FATTORI BIOLOGICI 406
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 390
SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI 382
GD2 expression in breast cancer. 379
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 378
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 367
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor 363
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 360
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 350
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 350
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 334
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 325
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 324
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 319
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 318
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial 317
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 316
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 316
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 313
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 310
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 308
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 308
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 307
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 304
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 301
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 298
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer. 296
Tumor Stroma Manipulation By MSC 295
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 295
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 294
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 294
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 286
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 284
Achievements and unmet needs in the management of advanced ovarian cancer 281
Molecular Profile, as detected with Mass-Array Spectrometry (Sequenom platform), in primary and metastatic breast carcinoma treated with Exemestane + Everolimus 281
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 279
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 278
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 277
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 277
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 277
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 273
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 271
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 268
Immune characterization of breast cancer metastases: prognostic implications. 263
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 262
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 262
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 260
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 260
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 260
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer 258
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 255
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 254
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 254
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 254
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 253
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 252
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 252
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 250
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 250
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 249
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 247
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 247
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 245
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 239
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 239
Breast Location for De Novo Extramedullary Myeloid Sarcoma 235
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer 234
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 234
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 234
Prognostic Factors for Breast Cancer: an Immunomorphological Update 232
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 232
Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study 231
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 229
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 227
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 227
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 226
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 225
Timing for starting second-line therapy in recurrent ovarian cancer 224
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 224
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 224
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 223
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 221
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 218
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 216
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 216
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 215
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 215
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 213
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 210
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 208
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 208
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 208
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 207
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 205
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 203
Totale 28.582
Salva come PNG Salva come JPEG
Categoria #
all - tutte 160.233
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 160.233
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.574 0 0 0 0 0 369 364 456 266 465 345 309
2021/20223.347 133 383 286 129 124 264 152 199 366 301 594 416
2022/20236.486 494 585 344 417 410 514 111 388 2.573 114 325 211
2023/20243.725 179 203 239 292 496 314 342 569 150 204 298 439
2024/20259.842 357 209 270 727 1.882 1.501 628 693 967 583 772 1.253
2025/20268.218 1.211 601 1.616 1.833 2.728 229 0 0 0 0 0 0
Totale 43.906